食管癌患者长程分次MR引导放化疗的临床实施与可行性:一项R-IDEAL 1b/2a期技术创新的评估
这项R-IDEAL 1b/2a期研究在1.5T MR-Linac上对食管癌患者实施长程分次在线自适应MR引导放化疗并缩小CTV-to-PTV margins,描述了工作流程与可行性。9例患者中183/212次(86%)计划分次在MR-Linac上成功完成,中位每次时间53分钟(IQR=3分钟),每日自适应计划靶区覆盖相似而心脏和肺平均剂量分别降低26%和12%。作者认为该方案中等可行并能更好保护心肺,建议未来研究优化和加速当前工作流程。
要点
- 9例食管癌患者中183/212次(86%)计划分次在MR-Linac上成功完成。
- 中位每次治疗时间53分钟(IQR=3分钟),符合≤60分钟可行性定义。
- 每日自适应计划心脏和肺平均剂量分别降低26%和12%。
核心结论
- 每日在线自适应分次放化疗并缩小PTV margins对食管癌中等可行,并能更好保护心脏和肺。
- 作者建议未来研究应聚焦于进一步优化和加速当前工作流程。
研究设计与样本
- R-IDEAL 1b/2a期研究,描述食管癌患者长程分次在线自适应MR引导放化疗的工作流程与可行性。
- 患者计划接受放化疗并在1.5T MR-Linac上治疗,每日采集MR图像用于在线轮廓适应和重新计划。
- 轮廓手动调整以匹配每日解剖,采用各向同性6 mm的CTV-to-PTV margin。
- 记录工作流程各步骤时间,可行性定义为在台时间≤60分钟,患者耐受性定义为>95%的分次在MR-Linac上完成。
- 回顾性分析定位验证和治疗后MRI,并将剂量学参数与标准非自适应常规治疗计划比较。
主要发现
- 9例食管癌患者接受放化疗,其中8例接受41.4 Gy分23次,1例接受50.4 Gy分28次。
- 4例患者所有计划分次均在MR-Linac上完成,2例患者因不适>5%的分次改至常规直线加速器。
- 212次计划分次中183次(86%)在MR-Linac上成功完成。
- 3次分次因技术问题提前结束,26次分次改至常规直线加速器,原因包括MR-Linac停机(n=10)、后勤原因(n=3)或不适(n=13)。
- 中位每次时间53分钟(IQR=3分钟);每日自适应MR-Linac计划靶区覆盖相似,危及器官剂量较常规治疗显著降低,肺和心脏平均剂量分别降低26%和12%。
关键数值与推荐
- 可行性定义为在台时间≤60分钟,本研究中位每次时间53分钟(IQR=3分钟)。
- 患者耐受性定义为>95%的分次在MR-Linac上完成,本研究212次计划分次中183次(86%)在MR-Linac上成功完成。
- 采用各向同性6 mm的CTV-to-PTV margin。
- 8例接受41.4 Gy分23次,1例接受50.4 Gy分28次。
- 每日自适应MR-Linac计划靶区覆盖相似,肺和心脏平均剂量分别降低26%和12%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出未来研究应聚焦于进一步优化和加速当前工作流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This R-Ideal stage 1b/2a study describes the workflow and feasibility of long-course fractionated online adaptive MR-guided chemoradiotherapy with reduced CTV-to-PTV margins on the 1.5T MR-Linac for patients with esophageal cancer. METHODS: Patients with esophageal cancer scheduled to undergo chemoradiation were treated on a 1.5T MR-Linac. Daily MR-images were acquired for online contour adaptation and replanning. Contours were manually adapted to match the daily anatomy and an isotropic CTV-to-PTV margin of 6 mm was applied. Time was recorded for all individual steps in the workflow. Feasibility and patient tolerability were defined as on-table time of ≤60 min and completion of >95% of the fractions on the MR-Linac, respectively. Positioning verification and post-treatment MRIs were retrospectively analyzed and dosimetric parameters were compared to standard non-adaptive conventional treatment plans. RESULTS: Nine patients with esophageal cancer were treated with chemoradiation; eight patients received 41.4 Gy in 23 fractions and one received 50.4 Gy in 28 fractions. Four patients received all planned fractions on the MR-Linac, whereas for two patients >5% of fractions were rescheduled to a conventional linac for reasons of discomfort. A total of 183 (86%) of 212 scheduled fractions were successfully delivered on the MR-Linac. Three fractions ended prematurely due to technical issues and 26 fractions were rescheduled on a conventional linac due to MR-Linac downtime (n = 10), logistical reasons (n = 3) or discomfort (n = 13).The median time per fraction was 53 min (IQR = 3 min). Daily adapted MR-Linac plans had similar target coverage, whereas dose to the organs-at-risk was significantly reduced compared to conventional treatment (26% and 12% reduction in mean lung and heart dose, respectively). CONCLUSION: Daily online adaptive fractionated chemoradiotherapy with reduced PTV margins is moderately feasible for esophageal cancer and results in better sparing of heart and lungs. Future studies should focus on further optimization and acceleration of the current workflow.
引用
- Boekhoff MR, Bouwmans R, Doornaert PAH, et al. Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation. Clin Transl Radiat Oncol. 2022. PMID: 35372703. doi:10.1016/j.ctro.2022.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。